Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.
Cocrystal Pharma, Inc. (Nasdaq: COCP) is a clinical-stage biotechnology company developing antiviral therapeutics that target the replication machinery of viruses such as influenza viruses, coronaviruses, noroviruses and hepatitis C viruses. This news page compiles company announcements, press releases and regulatory disclosures so readers can follow Cocrystal’s scientific, clinical and corporate developments over time.
Visitors can review updates on CDI-988, Cocrystal’s oral pan-viral 3CL protease inhibitor being advanced as a potential prevention and treatment for norovirus infections and for coronavirus infections. Recent news has highlighted FDA Investigational New Drug (IND) clearance, a Study May Proceed Letter for a Phase 1b human challenge study, Institutional Review Board approval at Emory University School of Medicine, and previously reported favorable Phase 1 safety and tolerability data.
The feed also covers progress in the company’s influenza programs, including oral and inhaled CC-42344 for pandemic and seasonal influenza A and an influenza A/B polymerase complex program supported by a National Institutes of Health Small Business Innovation Research (SBIR) Phase I award. Articles describe human challenge studies, preclinical findings against highly pathogenic avian influenza strains and external validation through government funding.
In addition to R&D news, this page includes capital markets and corporate updates, such as registered direct offerings, private placements of common stock and warrants, and conference presentations where Cocrystal’s leadership provides company overviews and clinical progress updates. Investors and observers can use this centralized news stream to follow key milestones, including clinical trial initiations, data presentations, grant awards and financing transactions related to COCP.
Cocrystal Pharma (Nasdaq: COCP) will present an overview and hold virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021. The conference will showcase the company's efforts in discovering and developing innovative antiviral therapeutics for various viruses, including influenza and SARS-CoV-2. Access to the webcast presentation is available through registration for the conference, starting from March 9 at 7:00 a.m. Eastern time to March 10 at 9:00 p.m. Eastern time.
Cocrystal Pharma (Nasdaq: COCP) announced its participation in the H.C. Wainwright Global Life Sciences Virtual Conference on January 9-10, 2021, where management will present a company overview and engage in virtual investor meetings. Interested participants can access the presentation by registering for the conference. The webcast will be available from March 9, 2021, at 7:00 a.m. Eastern time to March 10, 2021, at 9:00 p.m. Eastern time. Cocrystal specializes in developing antiviral therapeutics targeting various viruses, including SARS-CoV-2 and influenza.
Cocrystal Pharma (COCP) announced a presentation by President Sam Lee at the virtual 3rd Annual reimagine Health Research Symposium on January 21, 2021. Lee will discuss the company's structure-based drug design technology aimed at developing broad-spectrum antiviral therapies targeting COVID-19, influenza, and hepatitis C. Highlights include the progress of CC-31244, a Phase 2a HCV inhibitor, and CC-42344, an influenza A inhibitor expected to enter Phase 1 trials. The presentation emphasizes the platform's efficiency in drug discovery and its potential to combat high-value diseases.
Cocrystal Pharma (Nasdaq: COCP) has successfully completed its research obligations under its collaboration agreement with Merck within the initial two-year timeline. Merck will now assume full responsibility for the development of influenza A/B antiviral compounds discovered using Cocrystal's advanced technologies. This collaboration, praised for its efficacy, signifies a crucial step in addressing the urgent medical need for new influenza antivirals. Merck's ongoing development efforts will be crucial for these compounds’ future commercialization.
Cocrystal Pharma, Inc. (Nasdaq: COCP), a clinical-stage biotechnology company, announces that President Sam Lee, Ph.D., will present at the 3rd Annual reimagine Health Research Symposium on January 21, 2021. His presentation, titled “Application of structure-based drug design platform technology for developing broad spectrum COVID-19, influenza, and HCV antivirals,” will showcase the company's platform technology in antiviral drug discovery. Cocrystal recently selected a lead compound for its COVID-19 program, advancing its efforts against coronaviruses.
Cocrystal Pharma (Nasdaq: COCP), a clinical-stage biotechnology company, will present at NobleCon17 on January 19, 2021, at 2:15 p.m. ET. This annual investor conference focuses on innovative pharmaceutical developments, specifically novel antiviral therapeutics. The live presentation can be accessed at www.noblecon17.com, with a high-definition video available post-event on Cocrystal's website starting January 20, 2021. Cocrystal specializes in antiviral drugs targeting influenza, hepatitis C, coronaviruses, and noroviruses.
BOTHELL, Wash., Jan. 5, 2021 – Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that management will present at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The presentation will be accessible on the company’s website starting January 11, 2021, at 6:00 a.m. Eastern time. CEO Gary Wilcox highlighted the company's progress in advancing its pipeline of novel antiviral compounds during 2020 and expressed anticipation for discussing upcoming milestones at the conference.
For more details about Cocrystal, visit www.cocrystalpharma.com.
Cocrystal Pharma, Inc. (Nasdaq: COCP) has selected CDI-45205 as its lead compound for developing antiviral treatments targeting coronaviruses, including SARS-CoV-2. This compound, acquired under an exclusive licensing agreement from Kansas State University, has shown promise in preclinical studies. Cocrystal plans to initiate API synthesis and IND-enabling studies for CDI-45205, which may be delivered through injection or inhalation. The company also aims to develop additional oral coronavirus inhibitors using its proprietary technology. These efforts are viewed as complementary to existing COVID-19 vaccines.
Cocrystal Pharma (COCP) reported its Q3 2020 results, revealing a revenue of $489,000, slightly down from $492,000 year-over-year. The company closed the quarter with $31.8 million in cash, enabling the expansion of COVID-19 and Influenza A programs. Key developments include positive in vitro data for lead molecule CC-42344 against influenza and ongoing collaborations with Merck for influenza antiviral agents. Net losses increased to $2.67 million, reflecting higher R&D expenses due to COVID-19 initiatives. The company anticipates advancing its IND-enabling studies and initiating Phase 1 trials in 2021.
Cocrystal Pharma, Inc. (NASDAQ: COCP) announced that Dr. Gary Wilcox and Dr. Sam Lee will present at the World Antiviral Conference on November 12, 2020, at 1:20 PM EST. Their presentation will cover novel antiviral therapeutics targeting coronaviruses and influenza A strains. Cocrystal's proprietary technology aims to develop broad-spectrum influenza antivirals and COVID-19 treatments, with promising in vitro activity against SARS-CoV-2. The company expects to choose its lead preclinical molecule by year-end 2020.
FAQ
What is the current stock price of Cocrystal Pharma (COCP)?
What is the market cap of Cocrystal Pharma (COCP)?
